$545.94
3.03% yesterday
Nasdaq, Aug 11, 10:02 pm CET
ISIN
US75886F1075
Symbol
REGN

Regeneron Pharmaceuticals Stock price

$545.94
-21.80 3.84% 1M
-119.52 17.96% 6M
-166.39 23.36% YTD
-575.15 51.30% 1Y
-77.96 12.50% 3Y
-52.92 8.84% 5Y
-21.05 3.71% 10Y
+537.12 6,089.80% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-17.06 3.03%
ISIN
US75886F1075
Symbol
REGN
Industry

Key metrics

Basic
Market capitalization
$57.9b
Enterprise Value
$53.1b
Net debt
positive
Cash
$7.5b
Shares outstanding
106.4m
Valuation (TTM | estimate)
P/E
13.3 | 15.6
P/S
4.1 | 4.4
EV/Sales
3.7 | 4.0
EV/FCF
14.9
P/B
1.9
Financial Health
Equity Ratio
77.7%
Return on Equity
15.0%
ROCE
11.8%
ROIC
12.6%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$14.2b | $13.7b
EBITDA
$4.6b | $4.6b
EBIT
$4.1b | $4.3b
Net Income
$4.5b | $3.8b
Free Cash Flow
$3.6b
Growth (TTM | estimate)
Revenue
5.4% | -3.8%
EBITDA
-1.1% | -3.0%
EBIT
-2.6% | 1.3%
Net Income
3.2% | -13.0%
Free Cash Flow
11.7%
Margin (TTM | estimate)
Gross
86.5%
EBITDA
32.2% | 33.4%
EBIT
28.6%
Net
31.4% | 28.1%
Free Cash Flow
25.0%
More
EPS
$41.1
FCF per Share
$33.4
Short interest
2.1%
Employees
15k
Rev per Employee
$940.0k
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Regeneron Pharmaceuticals forecast:

25x Buy
74%
8x Hold
24%
1x Sell
3%

Analyst Opinions

34 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
74%
Hold
24%
Sell
3%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
14,214 14,214
5% 5%
100%
- Direct Costs 1,925 1,925
9% 9%
14%
12,290 12,290
5% 5%
86%
- Selling and Administrative Expenses 3,087 3,087
9% 9%
22%
- Research and Development Expense 5,120 5,120
9% 9%
36%
4,570 4,570
1% 1%
32%
- Depreciation and Amortization 510 510
13% 13%
4%
EBIT (Operating Income) EBIT 4,060 4,060
3% 3%
29%
Net Profit 4,459 4,459
3% 3%
31%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Positive
Seeking Alpha
about 17 hours ago
Regeneron's Q2 showed strong earnings and cash flow, driven by DUPIXENT's growth and operational discipline, despite EYLEA's ongoing revenue decline. EYLEA faces intense competition and margin pressure, but DUPIXENT's expanding indications and LIBTAYO's solid performance offset these headwinds. Regeneron's oncology pipeline is advancing, highlighted by LYNOZYFIC's approval, while strategic move...
Positive
The Motley Fool
9 days ago
The healthcare industry has been a remarkable place for investors to build significant portfolio returns through the years. Companies that are providing life-saving medicines, devices, and other products are often at the forefront of innovation in the healthcare space, a durable industry that tends to be broadly resilient even in times of economic unrest.
Positive
The Motley Fool
10 days ago
Regeneron (REGN) Q2 EPS Jumps 53%
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 15,158
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today